Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?
Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?
复制标题
DOI：
10.1016/j.cmet.2016.10.009
复制
发表时间：
2017-02-07
期刊：
影响因子：
29
通讯作者：
von Herrath, Matthias
中科院分区：
文献类型：
--
作者：
Kolb, Hubert;von Herrath, Matthias
T细胞介导的免疫抑制仅短暂延迟新近发作的1型糖尿病患者的β细胞功能丧失。我们在这里认为，潜在的疾病过程是由先天免疫反应。诱导局部先天免疫的非极化功能状态将支持调节性T细胞发育和B细胞增殖。
T cell-directed immunosuppression only transiently delays the loss of beta cell function in recent-onset type 1 diabetes. We argue here that the underlying disease process is carried by innate immune reactivity. Inducing a non-polarized functional state of local innate immunity will support regulatory T cell development and b cell proliferation.